Leo-pharma A/s

Alan Stuart Jessiman

Patrick Stephen Johnson

Morten Dahl Sørensen

Mark Andrews

Mogens Larsen

Kevin Neil Dack

Kristoffer Maansson

Xifu Liang

Peter Andersen

Mia Nørreskov Burhardt

Lars Jørgensen

The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g., dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Small molecule modulators of IL-17

The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

The present invention relates to a compound according to general formula (I) wherein X represents N or CH; Ris &#x2014;CN, (C-C)alkyl, (C-C)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C-C)cycloalkyl(C-C)alkyl, (3-7 membered)heterocycloalkyl-(C-C)alkyl or (5-6 membered)heteroaryl-(C-C)alkyl; Ris halogen, cyano, (C-C)alkyl or (C-C)cycloalkyl; Ris halogen, cyano, (C-C)alkyl, (C-C)haloalkyl or (C-C)cycloalkyl; Ris (C-C)alkyl or (C-C)haloalkyl; Ris (C-C)alkyl, (C-C)cycloalkyl, (C-C)alkyl-(C-C)cycloalkyl, (C-C)cycloalkyl-(C-C)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or &#x2014;OR. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds. 

Heteroaromatic modulators of the retinoid-related orphan receptor gamma

The present invention relates to a compound according to general formula (I) wherein X represents N or CH; Ris &#x2014;CN, (C-C)alkyl, (C-C)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C-C)cycloalkyl(C-C)alkyl, (3-7 membered)heterocycloalkyl-(C-C)alkyl or (5-6 membered)heteroaryl-(C-C)alkyl; Ris halogen, cyano, (C-C)alkyl or (C-C)cycloalkyl; Ris halogen, cyano, (C-C)alkyl, (C-C)haloalkyl or (C-C)cycloalkyl; Ris (C-C)alkyl or (C-C)haloalkyl; Ris (C-C)alkyl, (C-C)cycloalkyl, (C-C)alkyl-(C-C)cycloalkyl, (C-C)cycloalkyl-(C-C)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or &#x2014;OR. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.

Growing community of inventors

Ballerup, Denmark

Alan Stuart Jessiman